
    
      Based on the results of NSABP(National Surgical Adjuvant Breast and Bowel Project) B27 trial,
      anthracyclines(A) and Taxanes(T) are most commonly recommended in neoadjuvant chemotherapy of
      breast cancer.

      Pirarubicin is one of anthracyclines and by embedding the DNA double stranded, which inhibits
      DNA replication and RNA synthesis, thereby impedes the rapid growth of cancer cells.

      Docetaxel in one of taxanes and by strengthening the tubulin polymerization, inhibiting of
      microtubule depolymerization and leading to the formation of stable non functional
      microtubule bundles, which destroys mitosis of tumor cells.
    
  